336 related articles for article (PubMed ID: 27649838)
21. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
22. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
23. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
24. Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.
Bellanca RF; Pinna A; Catania G; Belcastro E; Angi M; D'Amico Ricci G
Ocul Immunol Inflamm; 2023 Feb; 31(2):402-406. PubMed ID: 35113757
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
[No Abstract] [Full Text] [Related]
26. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
[No Abstract] [Full Text] [Related]
27. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
28. Intraocular Concentrations of Cytokines and Chemokines in a Unique Case of Nivolumab-Induced Uveitis.
Yoshida M; Kunikata H; Nakazawa T
Ocul Immunol Inflamm; 2020 Aug; 28(6):850-853. PubMed ID: 31012778
[TBL] [Abstract][Full Text] [Related]
29. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
30. Generalized Lichen Nitidus Following Anti-PD-1 Antibody Treatment.
Cho M; Nonomura Y; Kaku Y; Dainichi T; Otsuka A; Kabashima K
JAMA Dermatol; 2018 Mar; 154(3):367-369. PubMed ID: 29344609
[No Abstract] [Full Text] [Related]
31. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
[No Abstract] [Full Text] [Related]
32. [A case of myasthenia gravis complicated with chronic rheumatoid arthritis and Vogt-Koyanagi-Harada disease].
Egashira K; Yamamoto T; Tsuji S; Ohnishi A; Murai Y
Rinsho Shinkeigaku; 1987 Jul; 27(7):859-61. PubMed ID: 3665276
[No Abstract] [Full Text] [Related]
33. Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
Diamantopoulos PT; Stoungioti S; Anastasopoulou A; Papaxoinis G; Gogas H
Melanoma Res; 2018 Dec; 28(6):648-651. PubMed ID: 30169430
[TBL] [Abstract][Full Text] [Related]
34. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
35. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
36. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.
Suwa S; Tomita R; Kataoka K; Ueno S
Ocul Immunol Inflamm; 2022 Aug; 30(6):1522-1526. PubMed ID: 33797309
[TBL] [Abstract][Full Text] [Related]
37. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
38. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
[No Abstract] [Full Text] [Related]
39. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
40. Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer.
Thapa B; Khalid S; Vakili R; Ui J; Misbah S
Am J Ther; 2018; 25(6):e761-e763. PubMed ID: 29889678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
